

Electronic Supplementary Information

Design of novel chiral *N,N,O*-tridentate phenanthroline ligands and its application to enantioselective addition of organozinc reagents to aldehydes


Yuki Naganawa,* Tomoya Namba, Tomotaka Aoyama, Kentaro Shoji
and Hisao Nishiyama*

Department of Applied Chemistry, Graduate School of Engineering, Nagoya University,
Chikusa, Nagoya 464-8603, Japan


General Information. Infrared (IR) spectra were recorded on a JASCO FT/IR-230 spectrometer. ¹H NMR spectra were measured at 25 °C on a Varian Mercury 300 (300 MHz) spectrometer. Data were reported as follows: chemical shifts in ppm from tetramethylsilane as an internal standard, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = double-doublet, ddd = double-double-doublet, dt = double-triplet, m = multiplet, br = broad, and app = apparent), coupling constants (Hz), and assignment. ¹³C NMR spectra were measured at 25 °C on a Varian Mercury 300 (75 MHz) spectrometer with complete proton decoupling. Chemical shifts were reported in ppm from the residual solvent as an internal standard. High performance liquid chromatography (HPLC) was performed carried out on a JASCO GULLIVER 1500 series using 4.6 mm x 25 cm Daicel Chiral Coulmns. High-resolution mass spectra (HRMS) were performed on a double-focusing magnetic sector mass spectrometer JEOL JMS-700. For thin layer chromatography (TLC) analysis throughout this work, TLC Silica gel 60 F₂₅₄ were used. The products were purified by flash column chromatography on silica gel 60 N (Kanto, 60-210 μm).

In experiments requiring dry solvent, toluene and THF was purchased from Kanto Chemical Co. Inc. as “Dehydrated” and further purified by passing through neutral alumina under nitrogen atmosphere. Other common dry solvents were purchased from Kanto Chemical Co. Inc. and used as received. 1,10-Phenanthroline monohydrate (Kanto) was dried and purified by passing through silica gel pad prior to use. Diethylzinc was purchased from Kanto Chemical Co. Inc. and used as received. Aldehydes were used after distillation or column chromatography on silica gel.

•General procedure for the synthesis of BinThro ligands (S)-1




To a stirred solution of (*S*)-1,1'-binaphthyl-2,2'-diol derivative **i**^{S1} (1.21 g, 3.0 mmol) in THF (15 mL), *n*-BuLi (1.6M solution in hexane, 2.06 mL, 3.3 mmol) was added dropwise at -78 °C under Ar atmosphere. After stirring for 2 h at the same temperature, 1,10-phenanthroline (810 mg, 4.1 mmol) in THF (20 mL) was added dropwise to the resulting mixture, and the dark purple solution was stirred at the same temperature for additional 12 h. The reaction mixture was quenched with saturated aqueous NH₄Cl and extracted with ethyl acetate. The filtrated organic layer was dried over MgSO₄ and evaporated. The residue was used for the next step without further purifications.



To a stirred solution of the crude product **ii** in ethyl acetate (20 mL), MnO₂ (5.20 g, 60 mmol) was added at room temperature. The black suspension was kept stirred at 60 °C for 12 h. The resulting mixture was cooled down to room temperature and filtered through a celite pad to remove MnO₂. The combined organic layers were evaporated and resolved in MeOH (10 mL). To the stirred MeOH solution, 4 M HCl (1 mL) was added, and the mixture was stirred at 60 °C for 12 h. After that, water was added to the reaction mixture which was extracted three times with CHCl₃. The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by flash column chromatography (eluting with hexane/ethyl acetate = 2 : 1) to afford (*S*)-**1d** as an orange solid in overall 44% yield (716 mg, 1.3 mmol).


(*R*)-3-(1,10-Phenanthrolin-2-yl)-[1,1'-binaphthalen]-2-ol (**1a**)



IR (KBr): 3448, 3056, 1624, 1592, 1558, 1508 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ(ppm) = 9.03 (dd, *J* = 4.2, 1.5 Hz, 1H), 8.72 (s, 1H), 8.60 (d, *J* = 8.7 Hz, 1H), 8.47 (d, *J* = 9.0 Hz, 1H), 8.22 (dd, *J* = 4.8, 1.5 Hz, 1H) 8.01-7.95 (m, 3H) 7.85 (d, *J* = 8.7 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.72 -7.52 (m, 5H), 7.46 (m, 1H), 7.34-7.22 (m, 2H),


7.10 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 157.1, 155.2, 150.4, 144.4, 142.8, 137.4, 135.7, 135.6, 134.8, 133.6, 132.9, 128.7, 128.5, 128.0, 127.6, 127.5, 127.3, 126.9, 126.7, 126.4, 125.6, 125.5, 125.4, 124.8, 123.2, 122.8, 122.2, 121.4, 119.6$ (Three peaks were overlapped.); $[\alpha]_{\text{D}}^{24} = -274.2$ ($c = 0.5, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{32}\text{H}_{21}\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$) 449.1648. Found 449.1640.

(S)-3-(1,10-Phenanthrolin-2-yl)-[1,1'-binaphthalene]-2,2'-diol (1b)




IR (KBr) 3419, 1622, 1596, 1558, 1508, 1467 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): $\delta(\text{ppm}) = 9.06$ (dd, $J = 4.5, 2.1$, 1H), 8.77 (s, 1H), 8.58 (d, $J = 9.0$ Hz, 1H), 8.48 (d, $J = 8.7$ Hz, 1H), 8.24 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.98-7.83 (m, 5H), 7.59 (m, 1H), 7.44 (d, 1H), 7.35-7.13 (m, 7H); ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 156.6, 156.4, 151.4, 150.5, 144.3, 142.6, 137.6, 135.6, 135.5, 133.7, 129.5, 129.1, 128.7, 128.1, 127.9, 127.3, 126.9, 126.8, 126.1, 125.4, 125.2, 124.2, 123.4, 123.3, 122.9, 121.4, 119.2, 117.9, 115.7, 114.7$. (one peak was overlapped); $[\alpha]_{\text{D}}^{20} = -174.0$ ($c = 1.0, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{32}\text{H}_{21}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$) 465.1598. Found 465.1595.

(S)-3-(1,10-Phenanthrolin-2-yl)-2'-phenyl-[1,1'-binaphthalen]-2-ol (1c)



IR (KBr): 3470, 3050, 1622, 1592, 1557, 1507 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): $\delta(\text{ppm}) = 9.07$ (d, $J = 4.2, 1.5$ Hz, 1H), 8.54 (s, 1H), 8.44 (d, $J = 8.7$, 1H), 8.34 (d, $J = 8.7$, 1H), 8.20 (dd, $J = 7.8, 1.5$ Hz, 1H), 8.07 (d, $J = 8.4$ Hz, 1H), 7.98 (d, $J = 8.4$ Hz, 1H), 7.77-7.70 (m, 4H), 7.58 (dd, $J = 4.5, 4.2$ Hz, 1H), 7.52 (d, $J = 8.7$ Hz, 1H), 7.48-7.43 (m, 3H), 7.24 (m, 1H), 7.17-7.14 (m, 2H), 7.04-6.95 (m, 4H); ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 157.1, 155.9, 150.3, 144.4, 142.6, 142.3, 140.0, 137.2, 135.5, 135.3, 133.0, 132.8, 132.3, 128.8, 128.6, 128.4, 128.2, 127.8, 127.7, 127.6, 127.2, 127.1, 126.9, 126.61, 126.55, 126.4, 126.1, 126.0, 125.4, 124.5, 123.1, 122.6, 121.0, 120.7, 119.3$ (Three peaks were overlapped.); $[\alpha]_{\text{D}}^{21} = +19.3$ ($c = 1.0, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{32}\text{H}_{25}\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$) 525.1961. Found 525.1962.


(S)-3-(1,10-Phenanthrolin-2-yl)-2'-(p-tolyl)-[1,1'-binaphthalen]-2-ol (1d)



IR (KBr): 3433, 3055, 1624, 1592, 1558, 1508, 1467 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): $\delta(\text{ppm}) = 9.06$ (dd, $J = 4.5, 1.8$ Hz, 1H), 8.52 (s, 1H), 8.39 (d, $J = 8.7$ Hz, 1H), 8.34 (d, $J = 8.7$ Hz, 1H), 8.18 (dd, $J = 7.5, 1.8$ Hz, 1H), 8.05 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 7.8$ Hz, 1H), 7.76-7.69 (m, 4H), 7.57 (dd, $J = 8.4, 4.5$ Hz, 1H), 7.50-7.42 (m, 2H), 7.38-7.35 (m, 2H), 7.26 (m, 1H), 7.19-7.13 (m, 2H), 6.99 (m, 1H), 6.84 (s, 1H), 6.82 (s, 1H), 2.09 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 157.0, 155.8, 150.2, 144.3,$


142.5, 140.0, 139.4, 137.2, 135.5, 135.4, 133.0, 132.7, 132.2, 128.7, 128.5, 128.4, 128.0, 127.71, 127.68, 127.59, 127.2, 126.9, 126.6, 126.5, 126.2, 126.0, 125.3, 125.3, 124.6, 123.0, 122.6, 121.1, 120.7, 119.2, 21.2. (Two peaks were overlapped.); $[\alpha]_{\text{D}}^{22} = +100.6$ ($c = 1.0$, CHCl_3); HRMS (ESI) Calcd for $\text{C}_{39}\text{H}_{26}\text{N}_2\text{ONa}$ ($[\text{M}+\text{Na}]^+$) 561.1943. Found 561.1936.

(S)-2'-(3,5-Dimethylphenyl)-3-(1,10-phenanthrolin-2-yl)-[1,1'-binaphthalen]-2-ol (1e)




IR (KBr): 3436, 2924, 1623, 1598, 1557, 1508, 1467 cm^{-1} ; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ (ppm) = 9.06 (dd, $J = 3.9, 1.5$ Hz, 1H), 8.48 (s, 1H), 8.35 (d, $J = 8.7$ Hz, 1H), 8.30 (d, $J = 8.7$ Hz, 1H), 8.16 (dd, $J = 8.4, 2.1$ Hz, 1H), 8.04 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 8.1$ Hz, 1H), 7.78-7.68 (m, 4H), 7.56 (dd, $J = 8.1, 4.5$ Hz, 1H), 7.51 (d, $J = 9.3$ Hz, 1H), 7.45 (m, 1H), 7.28 (m, 1H), 7.20-7.15 (m, 2H), 7.08 (s, 2H), 7.00 (m, 2H), 6.58 (s, 1H), 1.99 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) = 156.7, 155.6, 150.1, 144.2, 142.28, 142.25, 140.1, 137.2, 136.2, 135.8, 135.3, 133.1, 132.7, 132.2, 128.5, 128.42, 128.39, 127.75, 127.66, 127.56, 127.45, 127.1, 127.0, 126.8, 126.5, 126.3, 126.1, 126.0, 125.3, 124.8, 122.9, 122.5, 121.1, 120.8, 119.0, 21.4. (Two peaks were overlapped.); $[\alpha]_{\text{D}}^{21} = +99.4$ ($c = 1.0$, CHCl_3); HRMS (ESI) Calcd for $\text{C}_{40}\text{H}_{28}\text{N}_2\text{ONa}$ ($[\text{M}+\text{Na}]^+$) 575.2094. Found 575.2097.

(S)-2'-(3,5-Bis(trifluoromethyl)phenyl)-3-(1,10-phenanthrolin-2-yl)-[1,1'-binaphthalen]-2-ol (1f)



IR (KBr) 3447, 1623, 1598, 1558, 1508, 1467 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ (ppm) = 9.07 (dd, $J = 2.1, 1.8$ Hz, 1H), 8.60 (s, 1H), 8.49 (d, $J = 8.7$ Hz, 1H), 8.43 (d, $J = 8.7$ Hz, 1H), 8.22 (dd, $J = 8.4, 2.1$ Hz, 1H), 8.11 (d, $J = 8.1$, 1H), 8.01 (d, $J = 8.4$ Hz, 1H), 7.88-7.82 (m, 5H), 7.70 (d, $J = 8.4$ Hz, 1H), 7.63-7.50 (m, 3H), 7.40-7.32 (m, 2H), 7.26-7.16 (m, 2H), 6.89 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) = 156.6, 155.9, 150.4, 144.4, 143.9, 142.7, 137.4, 136.8, 135.5, 135.0, 133.5, 133.3, 133.0, 129.9 (q, $J = 33$ Hz), 129.1(m), 128.7, 128.6, 128.3, 127.9, 127.8, 127.7, 127.2, 126.7, 126.6, 126.2, 125.4, 123.8, 123.2, 123.0 (q, $J = 270$ Hz), 122.9, 120.9, 119.7 (m), 119.1. (Two peaks were overlapped.); $[\alpha]_{\text{D}}^{20} = +148.4$ ($c = 1.0$, CHCl_3); HRMS (ESI) Calcd for $\text{C}_{40}\text{H}_{23}\text{N}_2\text{OF}_6$ ($[\text{M}+\text{H}]^+$) 661.1709. Found 661.1706.


(S)-2'-(3,5-Bis(trimethoxy)phenyl)-3-(1,10-phenanthrolin-2-yl)-[1,1'-binaphthalen]-2-ol (1g)



IR (KBr) 3974, 3931, 3819, 1593, 1505, 1465, 1203, 1153, 847 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ (ppm) = 9.00 (m, 1H), 8.41 (s, 1H), 8.21 (s, 2H), 8.11 (m, 2H), 7.97 (d, $J = 8.4$ Hz, 1H), 7.76 (d, J

= 8.7 Hz, 1H), 7.74 (m, 1H), 7.60 (s, 2H), 7.52-7.68 (m, 3H), 7.15-7.36 (m, 3H), 7.04 (m, 1H), 6.78 (m, 2H), 6.10 (t, $J = 2.4$ Hz, 1H), 3.41 (s, 6H) ; ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 159.2, 156.8, 155.4, 150.2, 144.3, 142.5, 140.0, 137.3, 135.7, 135.4, 133.1, 132.9, 132.3, 128.5, 128.0, 127.7, 127.6, 127.4, 126.8, 126.7, 126.5, 126.4, 126.2, 125.5, 125.3, 124.6, 123.1, 122.6, 121.2, 120.9, 119.2, 106.7, 99.4, 55.1$ (Two peaks were overlapped.); $[\alpha]_{\text{D}}^{27} = +235.0$ ($c = 1.0, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{40}\text{H}_{28}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$) 585.2178. Found 585.2173.


(S)-2'-Phenyl-3-(quinolin-2-yl)-[1,1'-binaphthalen]-2-ol (4a)



This ligand was synthesized according to general procedure using quinolone instead of 1,10-phenanthroline.

IR (KBr) 3462, 3050, 1602, 1508 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): $\delta(\text{ppm}) = 8.53$ (s, 1H), 8.35 (d, $J = 9.0$, 1H), 8.30 (d, $J = 9.3$, 1H), 8.06 (d, $J = 8.4$ 1H), 7.98 (d, $J = 7.8$ Hz, 1H), 7.95 (d, $J = 6.6$ Hz, 1H), 7.85 (d, $J = 8.1$, 1H), 7.80 (m, 1H), 7.74-7.68 (m, 2H), 7.56 (m, 1H), 7.49-7.44 (m, 2H), 7.38-7.35 (m, 2H), 7.29 (m, 1H), 7.23-7.15 (m, 2H), 7.04-6.94 (m, 4H); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) = 157.5, 155.3, 144.3, 142.1, 140.0, 137.5, 135.2, 132.8, 132.7, 131.7, 130.3, 128.6, 128.5, 128.2, 127.93, 127.91, 127.88, 127.5, 127.4, 127.3, 127.1, 126.8, 126.7, 126.4, 126.3, 126.2, 126.1, 125.5, 124.5, 122.8, 120.8, 120.4, 117.7.; $[\alpha]_{\text{D}}^{20} = +75.8$ ($c = 1.0, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{35}\text{H}_{23}\text{NO}$ ($[\text{M}+\text{H}]^+$) 474.1858. Found 474.1853.


(S)-2-(2-Methoxy-2'-phenyl-[1,1'-binaphthalen]-3-yl)-1,10-phenanthroline (4b)



This ligand was synthesized with simple protection of hydroxy group of ligand (S)-1c using NaH and MeI in THF solvent at room temperature.


IR (KBr) 3418, 1588, 1505, 1454, 1410, 1018, 851, 826, 752, 701 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): $\delta(\text{ppm}) = 9.25$ (dd, $J = 4.2, 1.5$ Hz, 1H), 8.59 (s, 1H), 8.25 (dd, $J = 8.4, 1.8$ Hz, 1H), 8.18 (d, $J = 8.4$ Hz, 1H), 8.05 (d, $J = 8.4$ Hz, 1H), 7.98-8.01 (m, 2H), 7.70-7.90 (m, 4H), 7.62 (m, 1H), 7.38-7.50 (m, 2H), 7.22-7.35 (m, 6H), 7.09-7.16 (m, 3H), 2.97 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): $\delta(\text{ppm}) = 157.4, 153.7, 150.6, 146.5, 146.4, 142.3, 140.4, 136.3, 135.8, 135.1, 133.9, 133.5, 133.0, 132.9, 131.9, 130.7, 129.24, 129.19, 129.0, 128.5, 128.3, 128.2, 128.1, 127.7, 127.6, 127.2, 127.1, 126.7, 126.63, 126.60, 126.5, 126.2, 125.9, 125.14, 125.06, 123.1, 61.5$; $[\alpha]_{\text{D}}^{27} = -33.8$ ($c = 0.5, \text{CHCl}_3$); HRMS (ESI) Calcd for $\text{C}_{39}\text{H}_{26}\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$) 539.2123. Found 539.2117.

•General procedure for the enantioselective addition of diethylzinc to aldehydes **2**.



To a solution of (S)-**1f** (2.64 mg, 0.004 mmol) in dry ether (1 mL) was added dropwise 1.0 M hexane solution of diethylzinc (400 μ L, 0.4 mmol) at 0 °C under Ar and stirred for 30 min. Aldehydes **5** (0.20 mmol) was then added to the resulting orange solution at the same temperature, and the stirring was maintained for 12 h. The mixture was quenched with saturated NH₄Cl solution, extracted with ethyl acetate and dried over MgSO₄. After concentration under reduced pressure, the residue was purified by column chromatography on silica gel (eluting with hexane/ethyl acetate) to give the desired product **3**.


(R)-1-(Biphenyl-4-yl)propanol (3a).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.26-7.62 (m, 9H), 4.66 (t, J = 6.9 Hz, 1H), 2.03 (br, 1H), 1.70-2.00 (m, 2H), 0.98 (t, J = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OJ-H, hexane/isopropanol = 95/5, flow rate = 1.0 mL/min, retention time; 36.8 min (*S*) and 40.0 min(*R*)). [e.r. = 95.1/4.9][e.e. = 90.2%]


(R)-1-(*o*-Tolyl)propan-1-ol (3b).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.46 (dd, J = 7.8, 1.8 Hz, 1H), 7.15-7.26 (m, 3H), 4.87 (t, J = 6.9 Hz, 1H), 2.35 (s, 3H), 1.72-1.85 (m, 3H), 1.00 (t, J = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OB-H, hexane/isopropanol = 95/5, flow rate = 0.5 mL/min, retention time; 11.7 min (*S*) and 15.3 min(*R*)). [e.r. = 95.4/4.6][e.e. = 90.8%]


(R)-1-(*m*-Tolyl)propan-1-ol (3c).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.07-7.27 (m, 4H), 4.57 (t, J = 6.4 Hz, 1H), 2.37 (s, 3H), 1.81(s, 1H), 1.72-1.86 (m, 3H), 0.92 (t, J = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S3}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OB-H, hexane/isopropanol = 95/5, flow rate = 0.5 mL/min, retention time; 12.4 min (*S*) and 14.2 min(*R*)). [e.r. = 95.5/4.5][e.e. = 91.0%]


(*R*)-1-(*p*-Tolyl)propan-1-ol (3d).



$^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm) = 7.26 (d, $J = 7.8$ Hz, 2H), 7.16 (d, $J = 7.8$ Hz, 2H), 4.57 (t, $J = 6.6$ Hz, 1H), 2.36 (s, 3H), 1.65-1.95 (d, $J = 6.6$ Hz, 3H), 0.92 (t, $J = 7.5$ Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OJ-H, hexane/isopropanol = 97/3, flow rate = 0.5 mL/min, retention time; 26.8 min (*R*) and 30.2 min(*S*)). [e.r. = 94.1/5.9][e.e. = 88.2%]


(*R*)-1-(4-Methoxyphenyl)propan-1-ol (3e).



$^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm) = 7.26 (d, $J = 8.4$ Hz, 2H), 6.88 (d, $J = 8.4$ Hz, 2H), 4.54 (t, $J = 6.9$ Hz, 1H), 3.81 (s, 3H), 1.62-1.84 (m, 3H), 0.90 (t, $J = 7.5$ Hz, 3H). The detailed spectral data has been reported in the literature.^{S4}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OD, hexane/isopropanol = 97/3, flow rate = 0.7 mL/min, retention time; 24.7 min (*R*) and 31.3 min(*S*)). [e.r. = 94.1/5.9][e.e. = 88.2%]


(*R*)-1-(4-Trifluoromethylphenyl)propan-1-ol (3f).



$^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm) = 7.60 (d, $J = 8.7$ Hz, 2H), 7.46 (d, $J = 8.7$ Hz, 2H), 4.69 (t, $J = 6.9$ Hz, 1H), 1.99 (br, 1H), 1.70-1.85 (m, 2H), 0.94 (t, $J = 7.5$ Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OJ-H, hexane/isopropanol = 98/2, flow rate = 1.0 mL/min, retention time; 18.8 min (*S*) and 20.0 min(*R*)). [e.r. = 96.7/3.3][e.e. = 93.4%]

(*R*)-1-(4-(1-Hydroxypropyl)phenyl)ethan-1-one (3g).




$^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm) = 7.92-7.96 (m, 2H), 7.42-7.45 (m, 2H), 4.69 (t, $J = 6.6$ Hz, 1H), 2.61 (s, 3H), 1.98 (br, 1H), 1.72-1.84 (m, 2H), 0.94 (t, $J = 7.2$ Hz, 3H); $[\alpha]_D^{25} = +31.6$ ($c = 1.0$, CHCl_3). The detailed spectral data has been reported in the literature.^{S5}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALPAK AD-H, hexane/isopropanol = 97/3, flow rate = 1.0 mL/min,

retention time; 21.6 min (*R*) and 23.4 min(*S*). [e.r. = 96.3/3.7][e.e. = 92.6%]


(*R*)-4-(1-Hydroxypropyl)benzonitrile (3h).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.61-7.65 (m, 2H), 7.44-7.47 (m, 2H), 4.69 (t, *J* = 6.3 Hz, 1H), 2.09 (br, 1H), 1.72-1.82 (m, 2H), 0.93 (t, *J* = 7.8 Hz, 3H). The detailed spectral data has been reported in the literature.^{S3}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALPAK AD-H, hexane/isopropanol = 97/3, flow rate = 0.8 mL/min, retention time; 49.1 min (*R*) and 53.0 min(*S*). [e.r. = 95.5/4.5][e.e. = 91.0%]


(*R*)-1-(Naphthalen-1-yl)propan-1-ol (3i).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 8.12 (m, 1H), 7.76-7.91 (m, 2H), 7.63 (d, *J* = 6.9 Hz, 1H), 7.45-7.53 (m, 3H), 5.39 (t, *J* = 6.9 Hz, 1H), 1.86-2.07 (m, 3H), 1.05 (t, *J* = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OD-H, hexane/isopropanol = 90/10, flow rate = 1.0 mL/min, retention time; 9.0 min (*S*) and 16.0 min(*R*). [e.r. = 97.3/2.7][e.e. = 94.6%]


(*R*)-1-(Naphthalen-2-yl)propan-1-ol (3j).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.82-7.86 (m, 3H), 7.77 (s, 1H), 7.45-7.52 (m, 3H), 4.76 (t, *J* = 6.9 Hz, 1H), 2.13 (br, 1H), 1.80-2.03 (m, 2H), 0.96 (t, *J* = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OD-H, hexane/isopropanol = 95/5, flow rate = 1.0 mL/min, retention time; 20.8 min (*S*) and 22.2 min(*R*). [e.r. = 94.9/5.1][e.e. = 89.8%]


(*R*)-*trans*-1-Phenylpent-1-en-3-ol (3k).



¹H NMR (300 MHz, CDCl₃): δ (ppm) = 7.21-7.41 (m, 5H), 6.58 (d, *J* = 16.2 Hz, 1H), 6.22 (dd, *J* = 16.2 Hz, 6.9 Hz) 4.22 (q, *J* = 6.9 Hz), 1.50-1.88 (m, 3H), 0.99 (t, *J* = 7.5 Hz, 3H). The detailed spectral data has been reported in the literature.^{S2}

The enantiomeric purity of the product was determined by HPLC analysis (Daicel CHIRALCEL OD-H, hexane/isopropanol = 90/10, flow rate = 0.5 mL/min, retention time; 18.4 min (*R*) and 28.2 min(*S*). [e.r. = 79.8/20.4][e.e. = 59.4%]

X-ray crystallographic analysis of (*S*)-3-(1,10-Phenanthrolin-2-yl)-2'-(*p*-tolyl)-[1,1'-binaphthalen]-2-ol (1d).



The product was recrystallized from toluene/diethyl ether/hexanes.

A specimen of $C_{39}H_{22}N_2O$, approximate dimensions 0.200 mm x 0.200 mm x 0.400 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured.

The integration of the data using a monoclinic unit cell yielded a total of 17382 reflections to a maximum θ angle of 25.12° (0.84 Å resolution), of which 8726 were independent (average redundancy 1.992, completeness = 98.8%, $R_{int} = 3.76\%$) and 7057 (80.87%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 7.8103(7)$ Å, $b = 17.0401(15)$ Å, $c = 20.5041(16)$ Å, $\beta = 97.144(2)^\circ$, volume = $2707.7(4)$ Å³, are based upon the refinement of the XYZ-centroids of reflections above $20 \sigma(I)$. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.9690 and 0.9840.

The final anisotropic full-matrix least-squares refinement on F^2 with 761 variables converged at $R1 = 4.41\%$, for the observed data and $wR2 = 9.88\%$ for all data. The goodness-of-fit was 1.149. The largest peak in the final difference electron density synthesis was $0.268 e^-/\text{Å}^3$ and the largest hole was $-0.198 e^-/\text{Å}^3$ with an RMS deviation of $0.044 e^-/\text{Å}^3$. On the basis of the final model, the calculated density was 1.311 g/cm^3 and $F(000)$, 1112 e^- .

Table 1. Sample and crystal data


Chemical formula	$C_{39}H_{22}N_2O$	
Formula weight	534.58	
Temperature	93(2) K	
Wavelength	0.71073 Å	
Crystal size	0.200 x 0.200 x 0.400 mm	
Crystal system	monoclinic	
Space group	P 1 21 1	
Unit cell dimensions	$a = 7.8103(7)$ Å	$\alpha = 90^\circ$
	$b = 17.0401(15)$ Å	$\beta = 97.144(2)^\circ$
	$c = 20.5041(16)$ Å	$\gamma = 90^\circ$
Volume	$2707.7(4)$ Å ³	
Z	4	
Density (calculated)	1.311 g/cm ³	
Absorption coefficient	0.079 mm ⁻¹	
F(000)	1112	

Table 2. Data collection and structure refinement

Theta range for data collection	2.33 to 25.12°
Index ranges	-9<=h<=7, -19<=k<=20, -20<=l<=24
Reflections collected	17382
Independent reflections	8726 [R(int) = 0.0376]
Absorption correction	multi-scan
Max. and min. transmission	0.9840 and 0.9690
Refinement method	Full-matrix least-squares on F ²
Refinement program	SHELXL-2013 (Sheldrick, 2013)
Function minimized	$\sum w(F_o^2 - F_c^2)^2$
Data / restraints / parameters	8726 / 1 / 761
Goodness-of-fit on F ²	1.149
Δ / σ_{\max}	0.018
Final R indices	7057 data; R1 = 0.0441, wR2 = 0.0911 I > 2 σ (I) all data R1 = 0.0659, wR2 = 0.0988
Weighting scheme	$w = 1 / [\sigma^2(F_o^2) + (0.0409P)^2]$ where $P = (F_o^2 + 2F_c^2) / 3$
Absolute structure parameter	0.1(8)
Largest diff. peak and hole	0.268 and -0.198 eÅ ⁻³
R.M.S. deviation from mean	0.044 eÅ ⁻³

References.

- (S1) M. Ichinose, H. Suematsu, Y. Yasutomi, Y. Nishioka, T. Uchida and T. Katsuki, *Angew. Chem., Int. Ed.*, 2011, **50**, 9884.
- (S2) M. Hatano, T. Miyamoto and K. Ishihara, *J. Org. Chem.* **2006**, *71*, 6474.
- (S3) S. Yi-Shan, R. Boobalan, C. Chen and G.-H. Lee, *Tetrahedron: Asymmetry* **2014**, *25*, 327.
- (S4) Y.-J. Chen, R.-X. Lin and C. Chen, *Tetrahedron: Asymmetry* **2004**, *15*, 3561.
- (S5) T. Werner, A. M. Riahi and H. Schramm, *Synthesis* **2011**, 3482.



1a

